research use only

Vernakalant (RSD1235) Hydrochloride Potassium Channel inhibitor

Cat.No.E0144

Vernakalant (RSD-1235, MK-6621) is a novel, frequency-dependent Na+ channel and early activating K+ channel blocker that selectively prolongs the atrial refractory period.

Vernakalant (RSD1235) Hydrochloride Potassium Channel inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 385.93

Quality Control

Batch: E014401 DMSO]77 mg/mL]false]Water]77 mg/mL]false]Ethanol]77 mg/mL]false Purity: 99.84%
99.84

Chemical Information, Storage & Stability

Molecular Weight 385.93 Formula

C20H31NO4.ClH

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 748810-28-8 -- Storage of Stock Solutions

Synonyms MK-6621 Smiles Cl.COC1=C(OC)C=C(CCOC2CCCCC2N3CCC(O)C3)C=C1

Solubility

In vitro
Batch:

DMSO : 77 mg/mL ( (199.51 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 77 mg/mL

Ethanol : 77 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
K+ channel [1]
Na+ channel [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00125320 Completed
Atrial Fibrillation|Atrial Flutter
Astellas Pharma Inc|Astellas Pharma US Inc.|Advanz Pharma
June 2004 Phase 3
NCT00115791 Completed
Atrial Flutter|Atrial Fibrillation
Astellas Pharma Inc|Advanz Pharma
June 2004 Phase 3
NCT00476112 Completed
Atrial Flutter
Advanz Pharma|Astellas Pharma US Inc.
August 2003 Phase 2|Phase 3
NCT00468767 Completed
Atrial Fibrillation
Advanz Pharma|Astellas Pharma US Inc.
August 2003 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map